Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent a promising therapeutic approach for glaucoma. This study will investigate ocular immune responses in glaucoma and how these responses are altered following GLP-1RA treatment.

In glaucoma, pro-inflammatory myeloid cells induce retinal ganglion cell death. We will examine monocyte infiltration and microglia activation in experimental glaucoma and the modulatory influence of glucagon-like peptide-1 receptor agonists (GLP1RA). Results will enhance our understanding of neuroinflammatory processes in glaucoma and clarify mechanisms behind GLP1RA-induced RGC rescue.

Characterizing immune pathway activations following IOP elevation will help guide the development of novel glaucoma therapies. GLP-1RAs are a promising treatment modality for glaucoma, and a clearer understanding of how they modify ocular monocytic phenotypes has direct implications for optimizing drug delivery strategies.

Glaucoma is a leading cause of irreversible vision loss with insufficient treatment options. Characterizing the neuroprotective effects of GLP-1RAs in ocular hypertension will help establish their therapeutic potential and provide greater insight into the mechanisms underlying neurodegeneration in glaucoma.